Interaction Index and Different Methods for Determining Drug Interaction in Combination Therapy

Studying and understanding the joint effect of combined treatments is important in pharmacology and in the development of combination therapies. The Loewe additivity model is one of the best general reference models for evaluating drug interactions. Based on this model, synergy occurs when the interaction index is less than one, while antagonism occurs when interaction index is greater than one. We expound the meaning of the interaction index, and propose a procedure to calculate the interaction index and its associated confidence interval under the assumption that the dose-effect curve for a single agent follows Chou and Talalay's median effect equation. In addition, we review four response surface models based on the Loewe additivity model using a single parameter to determine drug interactions. We describe each of these models in the context of Loewe additivity model and discuss their relative advantages and disadvantages. We also provide S-PLUS/R code for each approach to facilitate the implementation of these commonly used methods.

[1]  Maiying Kong,et al.  Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction , 2009, Statistics in biopharmaceutical research.

[2]  R. Herbst,et al.  Role of novel targeted therapies in the clinic , 2005, British Journal of Cancer.

[3]  T. Evans.  Highlights from the Tenth World Conference on Lung Cancer. , 2004, The oncologist.

[4]  Chris Gennings,et al.  A Statistical Approach to the Construction and Analysis of Isobolograms , 1988 .

[5]  A. Hill,et al.  The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .

[6]  Luc Bijnens,et al.  Design and Analysis of Drug Combination Experiments , 2005, Biometrical journal. Biometrische Zeitschrift.

[7]  L. Sheiner,et al.  Understanding the Dose-Effect Relationship , 1981, Clinical pharmacokinetics.

[8]  P. Bickel,et al.  Mathematical Statistics: Basic Ideas and Selected Topics , 1977 .

[9]  J J Martinez-Irujo,et al.  Analysis of the combined effect of two linear inhibitors on a single enzyme. , 1998, The Biochemical journal.

[10]  Hong-Bin Fang,et al.  Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures , 2003, Statistics in medicine.

[11]  J Jack Lee,et al.  A semiparametric response surface model for assessing drug interaction. , 2008, Biometrics.

[12]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[13]  J. Gaddum.  Probit Analysis , 1948, Nature.

[14]  S. Crawford,et al.  Analysis of Quantal Response Data , 1994 .

[15]  S G Machado,et al.  A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments. , 1994, Statistics in medicine.

[16]  P. Sorger,et al.  Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.

[17]  R. L. Plackett,et al.  Quantal Responses to Mixtures of Poisons , 1952 .

[18]  Ronald J. Tallarida,et al.  Drug Synergism and Dose-Effect Data Analysis , 2000 .

[19]  M. Danhof,et al.  Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. , 2005, Pharmacology & therapeutics.

[20]  John Leyden. Webb,et al.  Enzyme and metabolic inhibitors , 1963 .

[21]  Berenbaum Mc.  What is synergy? , 1989, Pharmacological reviews.

[22]  W. Curran.  Evolving chemoradiation treatment strategies for locally advanced non-small-cell lung cancer. , 2003, Oncology.

[23]  K A Bachmann,et al.  The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions. , 2001, Current drug metabolism.

[24]  C. Belka,et al.  Isobologram analysis of triple therapies , 2006, Radiation oncology.

[25]  W R Greco,et al.  Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. , 1990, Cancer research.

[26]  M. Berenbaum.  What is synergy? , 1989, Pharmacological reviews.

[27]  W. Greco,et al.  The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.

[28]  J. Plummer,et al.  Statistical modeling of the effects of drug combinations. , 1990, Journal of pharmacological methods.

[29]  J Jack Lee,et al.  A Generalized Response Surface Model with Varying Relative Potency for Assessing Drug Interaction , 2006, Biometrics.

[30]  Gerhard Müller,et al.  CombiTool - A New Computer Program for Analyzing Combination Experiments with Biologically Active Agents , 1999, Comput. Biomed. Res..

[31]  C. I. Bliss.  THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .

[32]  R. Schinazi,et al.  Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. , 2004, Current topics in medicinal chemistry.